NASDAQ:ALKS
Alkermes plc Stock News
$24.02
-0.400 (-1.64%)
At Close: Apr 15, 2024
Incyte (INCY) Reports Positive Long-Term Data From HS Study
05:14pm, Monday, 13'th Feb 2023 Zacks Investment Research
Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
04:53pm, Monday, 13'th Feb 2023 Zacks Investment Research
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?
03:31pm, Monday, 13'th Feb 2023 Zacks Investment Research
On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
02:27pm, Monday, 13'th Feb 2023 Zacks Investment Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
04:30pm, Friday, 10'th Feb 2023 Zacks Investment Research
On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
04:01pm, Friday, 10'th Feb 2023 Zacks Investment Research
On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
02:26pm, Friday, 10'th Feb 2023 Zacks Investment Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?
04:27pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
02:36pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
03:00pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Biogen (BIIB) Beat Estimates This Earnings Season?
02:47pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
03:26pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
Alkermes Oncology Spinoff Could Eventuate An Alpha Play, Rate Buy
05:40am, Saturday, 07'th Jan 2023
Alkermes' planned spinoff of its oncology assets could establish a long-term compounder with interesting economics tied in. Financial details on the planned move are light, with further information se
Alkermes to Present at the 41st Annual J.P. Morgan Healthcare Conference
04:00pm, Wednesday, 28'th Dec 2022
DUBLIN , Dec. 28, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 41st Annual J.P.
Analyst Ratings for Alkermes
09:04pm, Tuesday, 06'th Dec 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Alkermes (NASDAQ:ALKS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a compan
